CEO Executive AssistantClinical development is the function that determines whether a pharmaceutical company’s pipeline reaches patients. Trial design, site selection, patient enrollment, data management, safety monitoring, and regulatory submission are all complex, high-stakes activities with consequences that can affect patients, the company, and the public. The CEO is responsible for clinical development outcomes but must not personally manage clinical development operations.
Building a delegation matrix for clinical development is one of the most important organizational design acts a pharma CEO undertakes. This matrix defines who owns which clinical development decisions, where the CEO’s involvement begins and ends, and how information flows between clinical operations and executive leadership.
The Structure of Clinical Development Leadership
Clinical development in a pharmaceutical company is typically led by a Chief Medical Officer (CMO) and a Head of Clinical Operations (or VP of Clinical Operations), often with additional senior leadership for specific functions such as regulatory affairs, data management, pharmacovigilance, and biometrics.
The CEO’s primary clinical development relationship is with the CMO. The CMO translates the pipeline strategy into clinical programs, oversees medical and scientific decision-making across trials, and serves as the primary interface between clinical development and the CEO.
The Head of Clinical Operations manages the operational execution of trials: site management, monitoring, CRO relationships, trial timelines, and budget performance. Both roles report to the CEO, but the CEO’s primary strategic engagement is through the CMO.
Clinical Decision-Making: What Only the CEO Decides
There are clinical development decisions that require CEO involvement because of their strategic, financial, or organizational significance. These include:
Pipeline investment allocation decisions: which programs to advance to the next stage, which to discontinue, and how to allocate R&D capital across the portfolio. These decisions involve significant capital commitment and have strategic implications for the company’s competitive position.
Go/no-go decisions for late-stage programs: entering Phase 3, particularly for large and expensive pivotal trials, requires CEO-level endorsement because of the scale of investment and the significance of the program to organizational strategy.
Major regulatory strategy decisions: choosing an indication, target patient population, or regulatory pathway involves strategic trade-offs that extend beyond clinical science into commercial, financial, and policy considerations that require CEO synthesis.
Trial discontinuation for futility or safety: stopping a program is a significant decision with financial, scientific, and reputational implications that warrants CEO engagement.
Partnership and licensing decisions affecting clinical programs: if the organization is in-licensing a program or entering a co-development partnership, these are CEO-level transactions regardless of the clinical stage.
Everything below this threshold is the CMO and clinical operations team’s domain.
The Clinical Operations Delegation Matrix
The following delegation matrix defines ownership across core clinical development activities:
Trial design and protocol development: Owned by the CMO and medical leadership team. The CEO is not involved in protocol specifics. Strategic alignment discussions about trial design options and their commercial implications may involve the CEO if they affect the program’s competitive profile or commercial label strategy.
Site selection and activation: Owned by Clinical Operations. No CEO involvement in routine site selection.
CRO selection and management: Owned by Clinical Operations with significant decisions (major CRO contracts) reviewed at the COO or CEO level depending on contract size threshold.
Patient enrollment performance: Owned by Clinical Operations. CEO receives a summary in the clinical dashboard when enrollment is materially off plan.
Data management and biometrics: Owned by the Biometrics team (biostatistics, data management, and programming). CEO is not involved in operational data management.
Safety reporting and pharmacovigilance: Owned by the Pharmacovigilance team, with the CMO accountable for regulatory compliance. CEO is engaged immediately for serious safety signals that may affect the program’s risk-benefit profile.
Regulatory submissions: Owned by Regulatory Affairs with CMO oversight. CEO is engaged for the most strategically significant submissions: NDA, BLA, or major supplemental applications.
Data monitoring committee interactions: Owned by the CMO. CEO is not typically involved in DMC interactions but is briefed on significant findings.
For the foundational pharma CEO delegation framework that contextualizes this matrix within the broader organizational design, see pharma CEO delegation guide.
Building Clinical Development Reporting for the CEO
The CEO needs a clear, regular view of clinical development performance without receiving raw operational data from individual trials. Build a clinical development dashboard that the CMO updates monthly or biweekly.
This dashboard should include: program-level status (on track, at risk, or off track) for each active clinical program, key enrollment metrics, significant trial events (data readouts, regulatory interactions, safety findings), major upcoming milestones, and any issues requiring CEO decision or awareness.
This dashboard is the CEO’s primary clinical development information source in non-crisis periods. It replaces the CEO attending individual trial status meetings or receiving detailed operational reports from each program.
The CEO reviews this dashboard, asks questions of the CMO in their regular one-on-one meetings, and engages more deeply only when a program is at risk or a strategic decision is needed.
Managing External Scientific Relationships
The pharma CEO often has scientific advisory relationships, partnerships with academic institutions, or collaborations with key opinion leaders that have both scientific and business development significance. These relationships involve CEO engagement but should be supported by a dedicated function.
Scientific affairs or medical affairs teams manage the operational aspects of key opinion leader relationships: speaker bureau programs, advisory board coordination, investigator-initiated study support, and congress presence. The CEO engages the scientific community at the most senior levels: scientific advisory board meetings, major conference presentations, and strategic scientific partnership discussions.
Safety Governance and the CEO
Patient safety is an absolute priority in pharmaceutical development, and safety governance is a function that requires both appropriate delegation and meaningful CEO engagement.
The Chief Safety Officer or VP of Drug Safety manages the pharmacovigilance function: aggregate safety review, individual case safety report processing, regulatory safety reporting, and risk management plan development.
Safety governance committees, including the company’s Safety Review Board, meet regularly to review aggregate safety data and make risk-benefit assessments. The CEO is typically not a regular member of operational safety committees but is informed of significant safety decisions.
The CEO becomes directly engaged when: a safety finding is significant enough to affect the program’s risk-benefit profile, a safety-related regulatory action is possible, or a serious adverse event has public or patient safety implications requiring executive response.
Building a clear protocol for how serious safety findings reach the CEO is one of the most important governance structures in clinical development. This should include the threshold for immediate CEO notification, the format of the notification, and the decision rights for immediate protective actions.
According to Harvard Business Review, pharmaceutical leaders who build clear safety governance frameworks with defined decision rights respond faster and more consistently to safety concerns than those who manage safety through ad hoc processes.
CEO Engagement With Regulatory Milestones
Regulatory milestones are the most significant events in clinical development from a strategic perspective. Each major regulatory interaction, including End-of-Phase 2 meetings, Pre-NDA meetings, Advisory Committee hearings, and approval decisions, represents a strategic milestone that warrants CEO engagement.
The Regulatory Affairs function manages the operational aspects of these interactions: preparing briefing documents, coordinating meeting logistics, and drafting agency correspondence. The CMO leads the scientific discussions. The CEO participates in key regulatory milestones where CEO presence signals organizational commitment and where strategic decisions are most likely to be needed.
See pharma regulatory affairs for how the regulatory delegation framework connects to and supports the clinical development delegation matrix.
When Clinical Development Goes Off Script
The cleanest delegation system is tested by unexpected events: an unexpected safety finding, an enrollment crisis, a clinical hold, or a failed pivotal trial. These situations require rapid CEO engagement at exactly the moment the clinical and operations teams are most stressed.
Pre-build escalation protocols for the most likely adverse scenarios. Define who notifies the CEO, at what threshold, and through what channel. Practice the protocols with the clinical and communications teams. When the scenario occurs, the CEO knows their role and the team knows how to engage.
Conclusion
Clinical development delegation is not about reducing the CEO’s accountability for what happens in trials. It is about ensuring that the right expertise is making the operational decisions and that the CEO’s judgment and authority is brought to bear on the decisions that genuinely require it.
Build the delegation matrix, establish the CMO as the CEO’s primary clinical interface, create the dashboard that maintains strategic visibility, and build the escalation protocols that bring the CEO in at the right moments. The patients waiting for your pipeline’s medicines deserve both excellent clinical execution and clear-eyed strategic leadership. Effective delegation is what makes both possible simultaneously.
Related Reading
For further context, explore Delegation Matrix for Arts Nonprofit CEOs and Delegation Matrix for Automotive CEO: Capital Projects.